HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

mosapride

structure given in first source; gastrokinetic agent free of dopamine D2 receptor antagonist properties

Also Known As:

4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide; AS 4370; AS-4370; mosapride citrate; Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

Networked: 44 relevant articles (11 outcomes, 8 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ueno, Naohiko: 2 articles (01/2010 - 01/2006)
2.	Fujisaki, Shigeru: 2 articles (03/2008 - 02/2006)
3.	Yamaguchi, Taketo: 2 articles (08/2006 - 06/2005)
4.	Odaka, Takeo: 2 articles (08/2006 - 06/2005)
5.	Ito, Tsugutaka: 2 articles (12/2002 - 05/2002)
6.	Sharma, A: 1 article (01/2010)
7.	Satoh, Yoshiko: 1 article (01/2010)
8.	Mohanti, B K: 1 article (01/2010)
9.	Inui, Akio: 1 article (01/2010)
10.	Gogia, A: 1 article (01/2010)

Related Diseases

1.	Dyspepsia (Indigestion) 01/01/2008 - "However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment. " 02/01/2004 - "CONCLUSION: Mosapride was safe and effective in improving the symptoms and gastric empty of functional dyspepsia." 05/01/2002 - "AIM: To evaluate the efficacy of three dosage regimens of mosapride compared with placebo in the treatment of functional dyspepsia. " 05/01/2002 - "Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study." 03/01/2004 - "CONCLUSIONS: A prokinetic drug, mosapride improves the symptoms and the quality of life in patients with functional dyspepsia." Order ALL the reference details at left...
2.	Constipation 06/01/2005 - "Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients." 01/01/2010 - "Mosapride improved reflux and constipation evaluated by GSRS. " 06/01/2005 - "The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects." 06/01/2005 - "The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. " 01/01/2010 - "Given that mosapride has those beneficial aspects, it may be a useful prokinetic agent in treating diabetic patients with constipation." Order ALL the reference details at left...
3.	Gastroesophageal Reflux (GERD) 10/01/2003 - "The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease." 01/01/1998 - "METHODS: The effect of mosapride on oesophageal 24-h acid reflux variables was studied in 21 patients with GERD symptoms and a pre-entry total acid exposure time (pH < 4) of more than 5%. " 01/01/1998 - "The importance of motor dysfunction in the pathogenesis of gastro-oesophageal reflux disease (GERD) makes it interesting to examine the effect of mosapride on oesophageal acid exposure. " 01/01/1998 - "The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease." 01/01/2004 - "A combination of pantoprazole and mosapride is more effective than pantoprazole alone in providing symptomatic relief to patients with erosive GERD." Order ALL the reference details at left...
4.	Diabetes Mellitus 01/01/2006 - "These observations suggest that mosapride citrate may be useful in the treatment of appetite loss and improve the quality of life in patients with diabetes mellitus." 06/01/2002 - "METHODS: Thirty-four inpatients with Type II diabetes mellitus were randomly assigned to receive either mosapride (5 mg orally three times a day, n=17) or a placebo ( n=17) for 1 week (first study). " 06/01/2002 - "Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus." Order ALL the reference details at left...
5.	Ileus 04/01/2009 - "Considering mosapride ADRs profile, it is believed that this compound is useful in the treatment of diseases associated with decreased GI motility, including postoperative ileus." 04/01/2009 - "Mosapride and postoperative ileus." 11/01/2008 - "We assessed the effect of mosapride on postoperative ileus following colon surgery. " 11/01/2008 - "The results suggested that the period of postoperative ileus following hand-assisted laparoscopic colectomy can be shortened by treatment with mosapride." Order ALL the reference details at left...

Related Drugs and Biologics

1.	pantoprazole (Protonix)
2.	benzamide
3.	Fluvoxamine (Luvox)
4.	Cisapride (Propulsid)
5.	Famotidine (Pepcid)
6.	tandospirone
7.	Serotonin (5 Hydroxytryptamine)
8.	Metoclopramide (Reglan)
9.	itopride
10.	Lidocaine (Xylocaine)

Related Therapies and Procedures

1.	Lymph Node Excision (Lymph Node Dissection)
2.	Colonic Pouches (S Pouch)
3.	Injections
4.	Gastrostomy
5.	Gastroenterostomy

blog comments powered by Disqus

TREATMENT OPTIONS
for Dyspepsia,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 188 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>